The Centers for Medicare and Medicaid Services (CMS) released the 2025 Medicare Physician Fee Schedule (PFS) final rule and the 2025 Hospital Outpatient Prospective Payment System (OPPS) and ...

Wolfe NK, Schiff MD, Christopher AB, et al., on behalf of FORCE Investigators. The study made use of the FORCE (Fontan Outcomes Registry Using CMR Examinations) registry, which collects clinical and ...

Welcome to the Cardiovascular (CV) Dyad Leadership Strategic Planning Series! In episode two of four, Dr. Tom Draper talks with Mr. Adam DeJong and Dr. Malissa Wood about efforts required in the ...

Tetralogy of Fallot is the most common cyanotic congenital heart disease and requires surgical repair. Strategy and timing/type of intervention is variable and depends on clinical symptomatology and ...

Participation in ACC’s Reduce the Risk: PCI Bleed Campaign was associated with a significant reduction of bleeding events following PCI, according to a study published in Circulation: Cardiovascular ...

Benali K, Ninni S, Guenancia C, et al. After propensity score matching, patients who underwent catheter ablation (n = 288) and those treated with medical therapy alone (n = 288) did not present any ...

Herzig MS, Kennedy KF, Hawkins BM, Secemsky EA. The authors examined all patients undergoing peripheral vascular intervention for the indication of ALI in the National Cardiovascular Data Registry ...

A biodegradable polymer sirolimus-eluting stent (BP-SES) was noninferior to currently-used second-generation drug-eluting stents (DES) in terms of target lesion failure (TLF) at one year in patients ...

Results from the FLASH trial demonstrate the noninferiority of artificial intelligence-based fully automated quantitative coronary angiography (AI-QCA)-assisted PCI compared with optical coherence ...

The FAVOR III Europe trial showed that in patients with chronic or acute coronary syndrome, noninvasive functional testing of intermediate stenoses with quantitative flow ratio (QFR) resulted in more ...

The ACURATE IDE trial failed to demonstrate that the Acurate neo2 valve was noninferior to a commercially available valve. Patients with severe aortic stenosis were randomized to the Acurate neo2 self ...